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Sections of original work described in this manuscript have been published in a peer-reviewed scientific 
journal, namely: 
 
“Regioselective Reduction of 3-methoxymaleimides: An Efficient Method for the Synthesis of Methyl 5-
hydroxytetramates” Issa, F; Fischer, J; Turner, P; Coster, M.J.; J. Org. Chem., 2006, 71, 4703–4705. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joshua Fischer 
December 2007 
 
  
ii 
A B S T R A C T  
This thesis describes synthetic studies towards the HIV-1 integrase inhibitory natural products 
lithospermic acid and integramycin, resulting in a formal total synthesis of the former. 
A modular, flexible and convergent synthetic strategy to lithospermic acid was devised. In this approach, 
a Sonogashira coupling was used to unite the C1–C7 and C20–C27 fragments that were subsequently 
manipulated to then participate in the key step of the synthesis, a palladium-mediated carbonylative 
annulation. Reduction of the benzofuran nucleus with magnesium in methanol then provided the desired 
dihydrobenzofuran core of lithospermic acid. Various protecting group strategies were investigated to 
complete this sequence in an efficient manner. Further synthetic manipulations afforded the complete 
C1–C9/C19–C27 fragment, which was united with the C10–C18 fragment to deliver the entire carbon 
skeleton of lithospermic acid. A two step deprotection sequence was undertaken, however, 
complications with the final deprotective step prevented definitive proof that the total synthesis of 
lithospermic acid had been achieved. An alternate protecting group strategy was sought, and a formal 
total synthesis of lithospermic acid was achieved by intercepting an advanced intermediate from a 
previous total synthesis. Several strategies for the enantioselective synthesis of the dihydrobenzofuran 
core of lithospermic acid were evaluated, however, none proved successful. 
A synthetic route towards the tetramic acid subunit of integramycin was also investigated. 3-
Methoxymaleimide was constructed using known chemistry, and the regioselective reduction of this ring 
system was developed. Attempts to further functionalise this ring system were thwarted by difficulties 
associated with handling. The scope of the regioselective reduction was investigated on an array of N-
substituted methoxymaleimides with the procedure found to be generally high yielding and highly 
regioselective. 
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%  percentage yield 
!  reflux 
°C  degree/s Celsius 
Å  Angstrom, 10–10 metres 
Ac  acetyl 
AIDS  acquired immunodeficiency syndrome 
Anal.  analysis 
aq.  aqueous 
Ar  aryl or argon 
Asp  aspartic acid 
BArF  B(2,3-(CF3)2C6H3)4 
BBN  9-Borabicyclo[3.3.1]nonane 
Bn  benzyl 
br  broad 
Bu  butyl 
C  cysteine 
CCR5  chemokine receptor 5 
CC100  cytotoxic concentration for 100% of cells 
ca.  circa (approximately) 
calc.  calculated 
cm–1  reciprocal centimeters 
coe  cyclooctene 
Cys  cysteine 
"  chemical shift 
D  aspartic acid 
d  doublet/s  
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE  1,2-dichloroethane 
DEAD  diethyl azodicarboxylate 
DIAD  diisopropyl azodicarboxylate 
DKA  diketoacid 
DMAP  4-(dimethylamino)pyridine  
DMF  N,N-dimethylformamide 
viii 
DNA  deoxyribonucleic acid 
dppp  1,3-bisdiphenylphosphinopropane 
DIBAL–H diisobutylaluminium hydride 
E  glutamic acid 
ee  enantiomeric excess 
EDC  1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EI  electron impact 
equiv.   molar equivalent(s) 
Et  ethyl 
eV  electron Volts 
Glu  glutamic acid 
g  gram 
H  histidine 
h  hour/s 
HAART Highly active anti-retroviral therapy 
His  histidine 
HIV  human immunodeficiency virus 
HRMS  high resolution mass spectrometry 
Hz  Hertz 
IC50  concentration required to inhibit a given biological process by 50% 
i-Pr  isopropyl 
IN  integrase 
IR  infrared 
J  coupling constant 
K  Kelvin 
L  litre 
#  micro 
m  multiplet 
M  molar 
M+, M•+ molecular ion 
Me  methyl 
min  minutes 
MHz  megahertz 
mmol  millimole 
mol  mole 
ix 
m.p.  melting point 
MS  mass spectrometry 
m/z  mass to charge ratio 
n-BuLi  n-butyllithium 
NMR  nuclear magnetic resonance 
NNRTI  non-nucleoside reverse transcriptase inhibitor 
NRTI  nucleoside reverse transcriptase inhibitor 
Ph  phenyl 
PI  protease inhibitor 
PIC  pre-integration complex 
PMHS  polymethylhydrosiloxane 
ppm  parts per million 
p-TsOH para-toluenesulfonic acid 
pyr  pyridine 
q  quartet 
quant.  quantitative (yield) 
R  unspecified functional group 
Rf  retention factor 
RNA  ribonucleic acid 
rt  room temperature (25 °C) 
s  singlet 
t  triplet 
t-AmOH tert-amyl alcohol 
TBAF  tetrabutylammonium fluoride 
TBDPSE tert-butyldiphenylsilylethyl 
TBS  tert-butyldimethylsilyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
tlc  thin layer chromatography 
TMS  trimethylsilyl; tetramethylsilane 
Ts  tosyl 
USFDA  United States Food and Drug Administration 
v/v, w/v volume per volume, weight per volume 
x 
C O M P O U N D  N U M B E R I N G  
 
In general, the naming and numbering priorities used throughout this manuscript are those set down by 
IUPAC. Otherwise, the numbering system of lithospermic acid (21) and integramycin (47), set forth by 
Kelley et al.43 and Singh et al.54 respectively, are employed and are shown below. 
When discussing the 2,3-disubstituted-2,3-dihydrobenzofuran ring systems, the designations cis- and 
trans- refer to the relative configuration of the substituents, and unless otherwise noted, refer to the 
racemate. Further to this, diastereomeric compounds are assigned the same compound number but are 
distinguished by the stereochemical descriptor in the prefix. 
When discussing the tetramic acid subunit (C1–C5) of integramycin (47), IUPAC numbering 
designations are not utilised. For clarity, the numbering system of the parent compound, integramycin, 
(47) is utilised consistently throughout. 
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